Trial Profile
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Left Ventricular Systolic Dysfunction following Myocardial Infarction.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NP 202 (Primary)
- Indications Left ventricular dysfunction; Myocardial infarction
- Focus Therapeutic Use
- Sponsors Armaron Biosciences
- 30 Jul 2021 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Planned End Date changed from 1 Feb 2018 to 31 Aug 2018.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.